Login Register Cart 0
Generic placeholder image

Current Vascular Pharmacology

Editor-in-Chief

ISSN (Print): 1570-1611
ISSN (Online): 1875-6212

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Editorial

Inclisiran. A New Kid on the New Block for Treating Hypercholesterolaemia

Author(s): Vasilios G. Athyros, Chrysoula Boutari, Konstantinos Imprialos and Michael Doumas*

Volume 19, Issue 5, 2021

Published on: 28 April, 2020

Page: [449 - 450] Pages: 2

DOI: 10.2174/1570161118999200428225849

Price: $65

Next »
[1]
Cohen JC, Boerwinkle E, Mosley TH Jr, Hobbs HH. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med 2006; 354(12): 1264-272.
[http://dx.doi.org/10.1056/NEJMoa054013] [PMID: 16554528]
[2]
Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med 2017; 376(18): 1713-22.
[http://dx.doi.org/10.1056/NEJMoa1615664] [PMID: 28304224]
[3]
Schwartz GG, Steg PG, Szarek M, et al. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. N Engl J Med 2018; 379(22): 2097-107.
[http://dx.doi.org/10.1056/NEJMoa1801174] [PMID: 30403574]
[4]
Horton JD, Cohen JC, Hobbs HH. Molecular biology of PCSK9: its role in LDL metabolism. Trends Biochem Sci 2007; 32(2): 71-7.
[http://dx.doi.org/10.1016/j.tibs.2006.12.008] [PMID: 17215125]
[5]
Nishikido T, Ray KK. Non-antibody Approaches to Proprotein Convertase Subtilisin Kexin 9 Inhibition: siRNA, Antisense Oligonucleotides, Adnectins, Vaccination, and New Attempts at Small-Molecule Inhibitors Based on New Discoveries. Front Cardiovasc Med 2019; 5: 199.
[http://dx.doi.org/10.3389/fcvm.2018.00199] [PMID: 30761308]
[6]
Raal FJ, Kallend D, Ray KK, et al. Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia. N Engl J Med 2020; 382(16): 1520-30.
[http://dx.doi.org/10.1056/NEJMoa1913805] [PMID: 32197277]
[7]
Ray KK, Wright RS, Kallend D, et al. Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol. N Engl J Med 2020; 382(16): 1507-9.
[http://dx.doi.org/10.1056/NEJMoa1912387] [PMID: 32187462]
[8]
Wright RS, Collins MG, Stoekenbroek RM, et al. Effects of Renal Impairment on the Pharmacokinetics, Efficacy, and Safety of Inclisiran: An Analysis of the ORION-7 and ORION-1 Studies. Mayo Clin Proc 2020; 95(1): 77-89.
[http://dx.doi.org/10.1016/j.mayocp.2019.08.021] [PMID: 31630870]
[9]
Byrne P, Cullinan J, Mintzes B, Smith SM. UK deal over inclisiran. BMJ 2020; 368: m579.
[http://dx.doi.org/10.1136/bmj.m579] [PMID: 32071100]
[10]
Anagnostis P, Vaitsi K, Mintziori G, Goulis DG, Mikhailidis DP. Non-coronary atherosclerotic cardiovascular disease in patients with familial hypercholesterolaemia. Curr Med Res Opin 2020; 36(5): 731-40.
[http://dx.doi.org/10.1080/03007995.2020.1734783] [PMID: 32096673]

Rights & Permissions Print Cite
Article Metrics
87
1
© 2024 Bentham Science Publishers | Privacy Policy